Highlight of ASH was the MD Anderson guys presenting their institutions history with ruxo showing a survival advantage. They really went after the Mayo data. Was a hoot.
I'm not normally a fan of MDACC (see also Advexin), but it's nice to see someone having enough courage to call out (in a public, peer-reviewed format) crappy data from another institution. Much better than the silent backstabbing that usually goes on...
Unless otherwise indicated, this is the personal viewpoint of David
Miller and not necessarily that of Biotech Stock Research, LLC.
We're on Twitter at BiotechStockRsr